Hologic revenues in women's healthcare jump
Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million
Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million compared with net income of $344,000 in the year-earlier period. Company execs attributed the improvement in earnings to decreasing expenses associated with the company's planned reduction of its general radiography systems business and to increased revenues, which came largely from the continuing sales shift from film-based mammography products to the higher margin Selenia full-field digital mammography system.
During the current quarter, Hologic installed and recognized as revenue 35 Selenia systems, which drove a 40% increase in mammography revenues to $27.9 million. As of the end of the quarter, 74 of these units valued at $53 million were on back order. Digital detector sales contributed further, generating $3 million, up 34% from the year-earlier period. Revenues were down 10%, however, for equipment related to osteoporosis assessment, as company sales tallied just $16.5 million of this equipment compared with $18.5 million in 2Q 2004.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
